Bladder cancer-associated microbiota: Recent advances and future perspectives. Issue 1 (January 2023)

• Record Type: Journal Article
• Authors: Zhang, Wentao; Yang, Fuhan; Mao, Shiyu; Wang, Ruiliang; Chen, Haotian; Ran, Yuefei; Liu, Shenghua; Wu, Pengfei; Yan, Yang; Li, Wei; Zhang, Junfeng; Yao, Xudong
• Is Part Of: Heliyon. Volume 9:Issue 1(2023)
• Publication Date: 2023-01
• Subjects: Bladder cancer -- Microbiota -- Recurrence -- Prognosis -- Therapeutics; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2023.e13012
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: Recent evidence suggests that the human genitourinary microbiome plays a significant role in mediating the development and progression of urological tumors, including bladder cancer (BC). Clinicians widely recognize the role of Bacille Calmette Guérin (BCG), an attenuated Mycobacterium tuberculosis vaccine, in the management of intermediate- and high-risk NMIBC. However, compared to the large body of evidence on the gut microbiota and gastrointestinal tumors, limited information is available about the interaction between BC and the genitourinary microbiome. This is an expanding field that merits further investigation. Urologists will need to consider the potential impact of the microbiome in BC diagnosis, prevention of recurrence and progression, and treatment prospects in the future. This review highlights the approaches adopted for microbiome research and the findings and inadequacies of current research on BC.